Literature DB >> 2162371

Evidence of prevalent genital-type human papillomavirus infections in adults and children.

S A Jenison1, X P Yu, J M Valentine, L A Koutsky, A E Christiansen, A M Beckmann, D A Galloway.   

Abstract

Recombinant proteins encoded by the E2, E7, L1, and L2 open reading frames (ORF) of human papillomavirus (HPV) types 6b, 16, and 18 were used in Western blot assays to detect serum IgG antibodies in women attending a sexually transmitted diseases clinic (n = 92) and in hospitalized children (n = 81). Antibodies to late gene products (L1 or L2 ORF) were more common than antibodies to early gene products (E2 or E7), both in the adults and the children; overall, the antibody prevalences in the children and the sexually active adults were not significantly different. Human sera with high titers of antibodies to the HPV16 E7 recombinant protein immunoprecipitated the genuine HPV16 E7 protein from the cervical carcinoma cell line CaSki. As an independent measure of HPV infection, the polymerase chain reaction was used to detect HPV6b and HPV16 in oral mucosal scrapings from adults (n = 35) and preschool children (n = 21). In adults, HPV6b and HPV16 DNA were detected in 17% and 23% of oral mucosal samples, respectively. In preschool children, HPV6b and HPV16 DNA were found in 24% and 19% of oral samples, respectively.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162371     DOI: 10.1093/infdis/162.1.60

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Immortalization of primary human smooth muscle cells.

Authors:  N Perez-Reyes; C L Halbert; P P Smith; E P Benditt; J K McDougall
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

Review 2.  Local immunity and the uterine cervix: implications for cancer-associated viruses.

Authors:  J K Roche; C P Crum
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

3.  Sexual risk behavior in women with cervical human papillomavirus infection.

Authors:  B Sikström; D Hellberg; S Nilsson; C Brihmer; P A Mårdh
Journal:  Arch Sex Behav       Date:  1996-08

Review 4.  Oral sex and the transmission of viral STIs.

Authors:  S Edwards; C Carne
Journal:  Sex Transm Infect       Date:  1998-02       Impact factor: 3.519

5.  Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients.

Authors:  C Bleul; M Müller; R Frank; H Gausepohl; U Koldovsky; H N Mgaya; J Luande; M Pawlita; J ter Meulen; R Viscidi
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

6.  Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7.

Authors:  G W Demers; S A Foster; C L Halbert; D A Galloway
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

7.  Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus.

Authors:  P Le Cann; A Touze; N Enogat; D Leboulleux; C Mougin; M C Legrand; C Calvet; J M Afoutou; P Coursaget
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

8.  Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions.

Authors:  N Yaegashi; S A Jenison; J M Valentine; M Dunn; L B Taichman; D A Baker; D A Galloway
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

9.  The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells.

Authors:  C L Halbert; G W Demers; D A Galloway
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Progression of human papillomavirus type 18-immortalized human keratinocytes to a malignant phenotype.

Authors:  P J Hurlin; P Kaur; P P Smith; N Perez-Reyes; R A Blanton; J K McDougall
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.